Showing 23,074 news articles about PEP

Filters Content type: Editors' picks Topic: PEP

Post-exposure prophylaxis involves taking a 28-day course of anti-HIV drugs, after possible exposure to HIV. It may be used by healthcare workers (occupational PEP) or after sex (post-exposure prophylaxis after sexual exposure, PEPSE, also known as non-occupational PEP or nPEP).

Injectable & long-acting PrEP

Gilead cranks up Yeztugo first-year sales forecast to $1B on 'unprecedented launch trajectory'

Editor's pick
FiercePharma
11 May 2026
Government, leadership & policy

Canada: Manitoba declares public health emergency as HIV rates rise

Editor's pick
CBC
11 May 2026
Vaccinations & immunisations

British Columbia study underscores the importance of the shingles vaccine for people with HIV

Editor's pick
CATIE
12 May 2026
Activism & civil society

Fearless in the face of financial cuts: Alex Garner on HIV advocacy in 2026

Editor's pick
Los Angeles Blade
13 May 2026
Sexually transmitted infections prevention

Study shows doxyPEP’s diminished effectiveness against gonorrhea

Editor's pick
CIDRAP
13 May 2026
Behaviour change interventions

We Call Them “Hard to Reach.” They Just Don’t Respond to Us.

Editor's pick
AIDS United
13 May 2026
PrEP programmes & uptake

Sharing is caring: HIV prevention pills are being shared in PrEP ‘Stokvels'

Editor's pick
Health-E News
13 May 2026
PrEP science

Modelling study predicts PrEP efficacy driven by drug levels in cells: results in men match those previously reported in women

Editor's pick
i-Base
13 May 2026
Global health targets

HIV goals for 2030: England on-target for HIV-related mortality but not for diagnoses

Editor's pick
i-Base
14 May 2026
Sexually transmitted infections prevention

WHO issues first recommendation on doxycycline post-exposure prophylaxis to help prevent sexually transmitted infections

Editor's pick
World Health Organization
19 May 2026
People & personal stories

My diagnosis seemed like a death sentence – how have I survived for another 40 years?

Editor's pick
The Guardian
20 May 2026
Injectable & long-acting PrEP

Misinformation is coming for the anti-HIV jab. Let’s get ahead of it

Editor's pick
Bhekisisa
25 May 2026
Quality of life

Quality of Life in People Aging With HIV: Long-Term Study Insights

Editor's pick
TheBodyPro
25 May 2026
People & personal stories

R.I.P. Kiara St. James, Influential Transgender and HIV Advocate in New York

Editor's pick
POZ
25 May 2026
Activism & civil society

Former HIV Scotland boss ordered to repay embezzled £5,000 to similar charity

Editor's pick
HeraldScotland
25 May 2026
Sexually transmitted infections epidemiology

ECDC warns of growing spread of multidrug-resistant Shigella in Europe

Editor's pick
European Centre for Disease Prevention and Control (ECDC)
25 May 2026
Activism & civil society

Health Is Primary

Editor's pick
POZ
25 May 2026
The search for a cure

Can Gene Therapy Control HIV? Steven Deeks, M.D., Explains the Science—and the Caveats

Editor's pick
TheBodyPro
25 May 2026
People with limited treatment options

Can Long-Acting Regimens Solve Virologic Failure in Heavily Treatment-Experienced People With HIV?

Editor's pick
TheBodyPro
28 May 2026
Government, leadership & policy

“High public health treason”: LGBTQ+ advocates rage over Trump CDC removing mpox webpage

Editor's pick
LGBTQ Nation
28 May 2026
Injectable & long-acting PrEP

A Powerful H.I.V. Drug Lands in Zambia. But Will It Reach Those Who Need It?

Editor's pick
The New York Times (requires free registration)
28 May 2026
Retention & linkage to care

The Peer Coaching Program Getting Men Back on HIV/AIDS Treatment in South Africa

Editor's pick
Gates Foundation
28 May 2026
People & personal stories

My brother’s HIV seemed under control. So why did he die?

Editor's pick
The Irish Times
1 June 2026
Task shifting

South Africa: Why pharmacists still can’t prescribe ARVs, months after court gave the green light

Editor's pick
Spotlight
2 June 2026